| Similar Articles |
|---|
 |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.   |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
The Motley Fool
May 18, 2011
Brian Orelli |
5 Biotech ASCO Abstracts to Watch The biotech investors' Christmas in May is once again upon us, where investors and researchers alike will be able to find the synopsis of what will be presented at the American Society of Clinical Oncology annual meeting next month. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
July 29, 2011
Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool
December 19, 2008
Brian Orelli |
Open-Label Bites Drug Duo Pfizer and Celldex have to make the best of a bad situation. |
The Motley Fool
June 5, 2007
Brian Lawler |
Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note. |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
The Motley Fool
May 22, 2008
Brian Lawler |
All Is Not Lost for AstraZeneca's Iressa AstraZeneca's Iressa gets a little pep back. |
The Motley Fool
August 5, 2009
Brian Orelli |
Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
September 3, 2010
Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
December 5, 2006
Brian Lawler |
Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
June 21, 2007
Brian Lawler |
Onyx on the Clock The one-drug wonder's partner files a marketing application to expand the use of its lead drug. Investors, take note. |
The Motley Fool
December 8, 2010
Brian Orelli |
Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
December 11, 2008
Brian Orelli |
ASH Wrap-Up: Alphabet Soup and Drugs Let's take a look at the data that came out of the American Society of Hematology meeting regarding pharmaceutical companies' medications for blood diseases. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
June 6, 2007
Brian Lawler |
Is Telik Insane? Shares of Telik fall after the FDA puts a halt to trials with its lead drug. Even at this reduced share price, investors should stay far away from this pharma. |
The Motley Fool
September 23, 2009
Brian Orelli |
Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer. |
The Motley Fool
February 13, 2007
Brian Lawler |
Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
December 8, 2009
Brian Orelli |
Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer. |
The Motley Fool
June 4, 2007
Brian Orelli |
OXiGENE's Moving Ahead The drug maker reaches a deal with FDA on its lead compound. Investors, take note. |
The Motley Fool
August 27, 2007
Brian Orelli |
Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up. |
The Motley Fool
July 15, 2008
Brian Orelli |
Will a New Use Help Schering-Plough's Near-Blockbuster Drug? Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma. |
The Motley Fool
May 21, 2007
Mike Havrilla |
Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in. |
The Motley Fool
June 2, 2009
Brian Orelli |
Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again. |
The Motley Fool
December 14, 2010
Brian Orelli |
Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold. |
The Motley Fool
June 4, 2010
Brian Orelli |
This Cancer Drug's on a Roll Novartis' Afinitor scores another win. |
